US 11,673,888 B2
Bicyclic compounds as ATX inhibitors
Jérôme Hert, Basel (CH); Daniel Hunziker, Basel (CH); Patrizio Mattei, Basel (CH); Markus Rudolph, Basel (CH); Petra Schmitz, Basel (CH); and Patrick Di Giorgio, Basel (CH)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Sep. 28, 2020, as Appl. No. 17/34,240.
Application 17/034,240 is a division of application No. 16/569,459, filed on Sep. 12, 2019, granted, now 10,882,857.
Application 16/569,459 is a continuation of application No. PCT/EP2018/056324, filed on Mar. 14, 2018.
Claims priority of application No. 17161254 (EP), filed on Mar. 16, 2017.
Prior Publication US 2021/0009589 A1, Jan. 14, 2021
Int. Cl. C07D 471/04 (2006.01); C07D 401/14 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); C07D 405/14 (2006.01); C07D 495/04 (2006.01); C07D 498/04 (2006.01); C07D 513/04 (2006.01); C07D 519/00 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/2095 (2013.01); A61K 9/485 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 495/04 (2013.01); C07D 498/04 (2013.01); C07D 513/04 (2013.01); C07D 519/00 (2013.01)] 12 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Chemistry
wherein:
R1 is:
(i) pyridinyl substituted by R3, R4 and R5, or
(ii) pyridinyl-C1-6-alkyl substituted by R3, R4 and R5,
Y is
i) —OC(O)—, or
ii) —C(O)—;
W is
—C(O)—;
R2 is selected from the ring systems O, AO, AW, and AX:

OG Complex Work Unit Chemistry
R3 is C1-6-alkylcarbonylamino or heterocycloalkyl-C1-6-alkoxy;
R4 and R5 are independently selected from the group consisting of
i) H,
ii) halogen,
iii) halo-C1-6-alkyl, and
iv) C3-8-cycloalkyl;
m is 1 or 2; and
n is 1;
or a pharmaceutically acceptable salt thereof.